Posters
« Back
The Case for CASE: Computer-Assisted Structure Elucidation
EP23988
The Case for CASE: Computer-Assisted Structure Elucidation
Submitted on 25 Apr 2016

ACD/Labs
ACD/Labs
Poster Views: 676
View poster »
Poster Abstract
Computer-Assisted Structure Elucidation (CASE) has come to be a broadly accepted method for the derivation of novel or difficult chemical structures, especially those of natural products or drug metabolites and impurities. For completely error-free structure determination, one must first evaluate all isomers that truly match connectivity criteria defined by experiment – but it is impossible to do this manually without bias.

Modern NMR techniques give ever-increasing amounts of valuable data to substantiate structural evaluations, including lower limits of detection, and more information on connectivities. However, errors in published structures are rampant giving weight to the argument for computer-assisted evaluation of structures.

1. Nicolaou, KC; Snyder, SA. Angew. Chem. Int. Ed. Engl., 2005, Feb 4:44(7); 1012-44.
2. Elyashberg, ME; Williams, AJ; Blinov, KA. Nat. Prod. Rep., 2010, 27(9): 1296-1328.
3. Moser, A; Elyashberg, ME; Williams, AJ; Blinov, KA; DiMartino, JC. J. Cheminf., 2012 4:5.
4. Ravu, RR, et al. J. Nat Prod., 2015, 78(4): 924-8.
5. http://www.acdlabs.com/comm/elucidation/2015_05.php
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


MODEL-AD: Bioinformatics and Data ManagementMODEL-AD: Bioinformatics and Data Management
Bruce Lamb1, Michael Sasner2, Andrew Saykin1, Lara Mangravite3, Gregory Carter2

MODEL-AD: The Disease Modeling Project
M.Sasner1, A. Oblak2, H. Williams1, G. Howell1, B.T. Lamb2 and the MODEL-AD consortium

MODEL-AD: Genetic models of late-onset Alzheimer’s disease
*A. OBLAK1,2, G. CARTER3, G. R. HOWELL3, B. LOGSDON4, L. MANGRAVITE4, K. NHO2, L. OMBERG4, K. D. ONOS3, V. PHILIP3, C. PREUSS3, S. J. SUKOFF RIZZO3, M. SASNER3, L. SHEN1,2, A. J. SAYKIN1,2, P. TERRITO1,2, A. UYAR3, H. WILLIAMS3, B. T. LAMB1,5

Preclinical drug screening in new generation Alzheimer’s disease mouse models: The MODEL-AD Consortium Strategy
P.R. Territo1, S.J. Sukoff Rizzo2, K. Onos2, J.A. Meyer1, J. Peters1, S.C. Persohn1, B.R. McCarthy1, A.A. Riley1, S. Quinney1, D. Jones1, M. Sasner2, G. Howell2, H. Williams2, A.J. Oblak1, B.L. Lamb1 and the MODEL-AD consortium

Generating Unbiased Structural Alternatives for Automated Structure Verification
Sergey Golotvin, Rostislav Pol, Mikhail Elyashberg, Dimitris Argyropoulos and Karim Kassam